FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1926045487> ?p ?o ?g. }

• W1926045487 abstract "Background Colony stimulating factors (CSFs), also called haematopoietic growth factors, regulate bone marrow production of circulating red and white cells, and platelets. Some CSFs also mobilise the release of bone marrow stem cells into the circulation. CSFs have been shown to be neuroprotective in experimental stroke. Objectives To assess (1) the safety and efficacy of CSFs in people with acute or subacute ischaemic or haemorrhagic stroke, and (2) the effect of CSFs on circulating stem and blood cell counts. Search methods We searched the Cochrane Stroke Group Trials Register (last searched September 2012), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 4), MEDLINE (1985 to September 2012), EMBASE (1985 to September 2012) and Science Citation Index (1985 to September 2012). In an attempt to identify further published, unpublished and ongoing trials we contacted manufacturers and principal investigators of trials (last contacted April 2012). We also searched reference lists of relevant articles and reviews. Selection criteria We included randomised controlled trials recruiting people with acute or subacute ischaemic or haemorrhagic stroke. CSFs included stem cell factor (SCF), erythropoietin (EPO), granulocyte colony stimulating factor (G‐CSF), granulocyte‐macrophage colony stimulating factor (GM‐CSF), macrophage‐colony stimulating factor (M‐CSF, CSF‐1), thrombopoietin (TPO), or analogues of these. The primary outcome was functional outcome at the end of the trial. Secondary outcomes included safety at the end of treatment, death at the end of follow‐up, infarct volume and haematology measures. Data collection and analysis Two review authors (TE and NS) independently extracted data and assessed trial quality. We contacted study authors for additional information. Main results We included a total of 11 studies involving 1275 participants. In three trials (n = 782), EPO therapy was associated with a significant increase in death by the end of the trial (odds ratio (OR) 1.98, 95% confidence interval (CI) 1.19 to 3.3, P = 0.009) and a non‐significant increase in serious adverse events. EPO significantly increased the red cell count with no effect on platelet or white cell count, or infarct volume. Two small trials of carbamylated EPO have been completed but have yet to be reported. We included eight small trials (n = 548) of G‐CSF. G‐CSF was associated with a non‐significant reduction in early impairment (mean difference (MD) ‐0.4, 95% CI ‐1.82 to 1.01, P = 0.58) but had no effect on functional outcome at the end of the trial. G‐CSF significantly elevated the white cell count and the CD34+ cell count, but had no effect on infarct volume. Further trials of G‐CSF are ongoing. Authors' conclusions There are significant safety concerns regarding EPO therapy for stroke. It is too early to know whether other CSFs improve functional outcome." @default.
• W1926045487 created "2016-06-24" @default.
• W1926045487 creator A5013869274 @default.
• W1926045487 creator A5057794391 @default.
• W1926045487 creator A5079967649 @default.
• W1926045487 date "2013-06-24" @default.
• W1926045487 modified "2023-10-18" @default.
• W1926045487 title "Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke" @default.
• W1926045487 cites W1510574810 @default.
• W1926045487 cites W1522375197 @default.
• W1926045487 cites W1964717684 @default.
• W1926045487 cites W1979299324 @default.
• W1926045487 cites W1980285476 @default.
• W1926045487 cites W1981178584 @default.
• W1926045487 cites W1989806700 @default.
• W1926045487 cites W1994430783 @default.
• W1926045487 cites W2007856475 @default.
• W1926045487 cites W2014424956 @default.
• W1926045487 cites W2014648588 @default.
• W1926045487 cites W2020058660 @default.
• W1926045487 cites W2022361377 @default.
• W1926045487 cites W2025403677 @default.
• W1926045487 cites W2028034679 @default.
• W1926045487 cites W2031339431 @default.
• W1926045487 cites W2042613009 @default.
• W1926045487 cites W2049161368 @default.
• W1926045487 cites W2054629742 @default.
• W1926045487 cites W2059339846 @default.
• W1926045487 cites W2063272445 @default.
• W1926045487 cites W2065995663 @default.
• W1926045487 cites W2067821134 @default.
• W1926045487 cites W2068112437 @default.
• W1926045487 cites W2071277454 @default.
• W1926045487 cites W2080155661 @default.
• W1926045487 cites W2097950056 @default.
• W1926045487 cites W2099313362 @default.
• W1926045487 cites W2103036639 @default.
• W1926045487 cites W2103320383 @default.
• W1926045487 cites W2107261727 @default.
• W1926045487 cites W2109723592 @default.
• W1926045487 cites W2111750321 @default.
• W1926045487 cites W2112646710 @default.
• W1926045487 cites W2122623988 @default.
• W1926045487 cites W2122965222 @default.
• W1926045487 cites W2123658895 @default.
• W1926045487 cites W2130098213 @default.
• W1926045487 cites W2142463112 @default.
• W1926045487 cites W2142631525 @default.
• W1926045487 cites W2143058635 @default.
• W1926045487 cites W2162264368 @default.
• W1926045487 cites W2162914074 @default.
• W1926045487 cites W2165849080 @default.
• W1926045487 cites W2168820671 @default.
• W1926045487 cites W2172005768 @default.
• W1926045487 cites W2284986079 @default.
• W1926045487 cites W4255057869 @default.
• W1926045487 doi "https://doi.org/10.1002/14651858.cd005207.pub4" @default.
• W1926045487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23797623" @default.
• W1926045487 hasPublicationYear "2013" @default.
• W1926045487 type Work @default.
• W1926045487 sameAs 1926045487 @default.
• W1926045487 citedByCount "46" @default.
• W1926045487 countsByYear W19260454872013 @default.
• W1926045487 countsByYear W19260454872014 @default.
• W1926045487 countsByYear W19260454872015 @default.
• W1926045487 countsByYear W19260454872016 @default.
• W1926045487 countsByYear W19260454872017 @default.
• W1926045487 countsByYear W19260454872020 @default.
• W1926045487 countsByYear W19260454872022 @default.
• W1926045487 countsByYear W19260454872023 @default.
• W1926045487 crossrefType "journal-article" @default.
• W1926045487 hasAuthorship W1926045487A5013869274 @default.
• W1926045487 hasAuthorship W1926045487A5057794391 @default.
• W1926045487 hasAuthorship W1926045487A5079967649 @default.
• W1926045487 hasConcept C109159458 @default.
• W1926045487 hasConcept C126322002 @default.
• W1926045487 hasConcept C127413603 @default.
• W1926045487 hasConcept C143998085 @default.
• W1926045487 hasConcept C168563851 @default.
• W1926045487 hasConcept C203014093 @default.
• W1926045487 hasConcept C2776478404 @default.
• W1926045487 hasConcept C2776694085 @default.
• W1926045487 hasConcept C2777767877 @default.
• W1926045487 hasConcept C2777863708 @default.
• W1926045487 hasConcept C2778534260 @default.
• W1926045487 hasConcept C2780645631 @default.
• W1926045487 hasConcept C28328180 @default.
• W1926045487 hasConcept C54355233 @default.
• W1926045487 hasConcept C71924100 @default.
• W1926045487 hasConcept C78519656 @default.
• W1926045487 hasConcept C86803240 @default.
• W1926045487 hasConcept C880424 @default.
• W1926045487 hasConceptScore W1926045487C109159458 @default.
• W1926045487 hasConceptScore W1926045487C126322002 @default.
• W1926045487 hasConceptScore W1926045487C127413603 @default.
• W1926045487 hasConceptScore W1926045487C143998085 @default.
• W1926045487 hasConceptScore W1926045487C168563851 @default.
• W1926045487 hasConceptScore W1926045487C203014093 @default.
• W1926045487 hasConceptScore W1926045487C2776478404 @default.
• W1926045487 hasConceptScore W1926045487C2776694085 @default.

• next